Almirall: investors to focus on Lebrikizumab Pipeline, sales of which could peak at €450m

Almirall edificio id

Morgan Stanley: Analyst Thibault Boutherin expects the stock to be flat or slightly down post-results following the lowering of guidance for FY24, but reiterates that all medium-term drivers remain intact. Almirall posted EBITDA 3-4% below consensus and guidance for H1 2024 sales 2% below consensus and EBITDA 4% below consensus. However, Thibault expects investors to focus on the Lebrikizumab Pipeline, where sales could peak at €450 million.

ATT00003 2

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.